Our Research

Discover our recent findings, catch up with news, and review in-depth resources.

The Role of OGNTs in the Personalized Medicine Revolution

This paper highlights oligonucleotides (OGNTs) as a revolutionary new class of drugs in personalized medicine due to their targeted approach to genetic diseases.

Single-Day Protein LC-MS Bioanalysis

This paper explains how next-generation trypsins offer faster protein digestion for LC-MS analysis with comparable performance to standard methods.

In Vitro Models for Predicting Transporter-Mediated DDIs

This paper discusses how in vitro studies can be used to predict drug-drug interactions (DDIs) caused by transporters in the body.

A Singlicate Immunogenicity Method to Detect anti-PEG Antibodies

This paper proposes a new method to detect anti-PEG antibodies in serum, potentially improving the safety of PEG-based medications.

Development and Validation of Immunogenicity Assays for ADCs

CASE STUDY – DEVELOPMENT AND VALIDATION OF IMMUNOGENICITY ASSAYS FOR ADCs. Addressing ADC Regulatory Challenges by Providing Validated Assays for Multi-Domain Proteins…

Development and Validation of an Immunogenicity Assay for Detection of Anti-AAV Antibodies

CASE STUDY – ANTI-AAV ANTIBODIES. We are experienced with a wide range of different proteins and therapeutics…
Scroll to Top

What Makes a Good LC-MS/MS Bioassay?

What makes a good LC-MS/MS bioassay?

Liquid chromatography linked to tandem mass spectrometry (LC–MS/MS, LC-MS) is the “go-to” method for pharmacokinetics and metabolism studies across drug development with recent advances in separation, throughput and methods for analyzing protein biotherapeutics.

But not all LC-MS/MS assays are created equal. There are many pitfalls that await even experienced scientists developing and validating, for example, a new bioassay. However, with experience and knowing what pitfalls to look out for, these issues don’t need to stand in the way of producing a robust bioassay and achieving analysis goals for your compound in good time.

Choosing the right LC-MS method approach

When selecting your LC-MS/MS method approach it is worth doing your homework. Pick an assay format that is best suited to your compound and consider factors such as matrix type, analyte structure, choice and availability of reagents, and the sensitivity and specificity you need.

What about sample preparation? Will protein precipitation or solid phase extraction be enough or should you consider enrichment, for example using affinity capture steps? Use the simplest approach available to the required selectivity/specificity, sensitivity, accuracy, and precision in the intended matrix and species.

Common pitfalls of LC-MS assays

Accuracy, precision, reliability, throughput and sensitivity all make for a good assay. But what are the common pitfalls you should be on top of when commissioning a new LC-MS/MS assay?

The increase in sensitivity of recent LC-MS/MS instruments and the use of wide calibration ranges can make carry over and contamination an issue, but these can be avoided if detected and addressed during validation.

The retention factor of the analyte needs to be optimized in order to allow for the analyte to have sufficient time to interact with the stationary phase on the column. This will allow for the best sensitivity to be achieved and for the analyte to elute from the column before any other matrix interferences in the sample.

LC-MS/MS has a well-deserved reputation for excellent selectivity but interference from the sample matrix (matrix effect) or metabolites can catch you out. Careful validation is key to optimizing methods to eliminate or minimize these issues1.

Best recommendation for a robust LC-MS assay?

Find a partner with expertise in a wide range of LC-MS/MS methodologies

Resolian has extensive experience developing LC-MS/MS bioassays for many different compounds and applies an intelligent, streamlined process to new method development that highlights issues at an early stage and creates a solid basis for future troubleshooting.

Read our guide “A step-by-step guide to developing a robust assay in bioanalysis using LC-MS/MS” to learn about our proven approach to developing industry-leading LC-MS/MS bioassays.

Reference

1. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC− MS/MS. Analytical Chemistry. 2003 Jul 1;75(13):3019-30.

Zhiyang Zhao, Ph.D.

Chief Scientific Officer

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade. 

Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia. 

Patrick Bennett

Chief Executive Officer

Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now CEO at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD. 

Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.